Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2022-01-06

FDA Approved: STRATTERA — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for Strattera (atomoxetine hydrochloride) from Eli Lilly and Company, updating the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • STRATTERA (Atomoxetine hydrochloride)

Snippet

SUPPL AP for STRATTERA (ATOMOXETINE HYDROCHLORIDE)